EVT Evotec SE

DGAP-News: MUBADALA INVESTMENT COMPANY UND NOVO HOLDINGS A/S INVESTIEREN 250 MIO. € IN EVOTEC SE

DGAP-News: MUBADALA INVESTMENT COMPANY UND NOVO HOLDINGS A/S INVESTIEREN 250 MIO. € IN EVOTEC SE
DE
12/10/2020

Underlying

EVTEvotec SE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Evotec SE

Free Trial
EVT EVOTEC SE

Evotec SE: 1 director

A director at Evotec SE bought 20,000 shares at 5.475EUR and the significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

12/09/25 December 9, 2025 1 EN
Thomas J. Schiessle
  • Thomas J. Schiessle
EUR 290.00
EVT EVOTEC SE

Schwache Konjunktur verzögert weiterhin „Profitability Restart“ - Mone...

Q3/25-KPIs zeigen eine Umsatz- und EBITDA Margen-Verschlechterung (Umsatz -11% YoY auf € 164 Mio./Marge: -9,17 %; EPS € -0,24), doch sind diese durch Phasing-Effekte und Reset-Einsparungen überzeichnet. Die anhaltend schwache Nachfrage im Markt für frühe Arzneimittelforschung (D&PD) konnte das gut gelaufene Geschäft von Just-Evotec Biologics (JEB) nur teilweise ausgleichen. Zudem kämpft Evotec mit Unterauslastung. Hinzu kommen Kosten im Zusammenhang mit dem Anlaufen der JEB-Anlage im französisch...

11/07/25 November 7, 2025 5 DE
Thomas J. Schiessle
  • Thomas J. Schiessle
EUR 290.00
EVT EVOTEC SE

Weak economic conditions continue to delay the 'Profitability Restart'...

Q3/25 KPIs show a decline in revenue and EBITDA margins (revenue -11% YoY to €164m / margin: -9.17%; EPS € -0.24), but these are exaggerated due to phasing effects and reset savings. The persistently weak demand in the early drug discovery (D&PD) market could only partially offset the well-performing business of Just-Evotec Biologics (JEB). Additionally, Evotec is struggling with underutilization. There are also costs associated with the start-up of the JEB facility in Toulouse, France, which is...

11/07/25 November 7, 2025 4 EN
Roy Külter ... (+2)
  • Roy Külter
  • Steven Boumans
CRI CHARGEURS SA
BVI BUREAU VERITAS SA
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
EVT EVOTEC SE
TNG TRANSGENE SA
ISS ISS A/S
ITRK INTERTEK GROUP PLC
BOSS HUGO BOSS AG
ACX ACERINOX SA
TRI TRIGANO SA
FAE FAES FARMA S.A.
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
ROYAL VOPAK NV
MONT MONTEA SCA
BPOST BPOST SA
CPINV CARE PROPERTY INVEST SA
TWEKA TKH GROUP N.V. CERT
DGM DIAGNOSTIC MEDICAL SYSTEMS
RUI RUBIS SCA
DIGI DIGI COMMUNICATIONS NV
GEST GESTAMP AUTOMOCION S.A.
ALFEN ALFEN NV
HFG HELLOFRESH SE
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
AG1 AUTO1 GROUP
SGSN SGS SA
SHA SCHAEFFLER AG
11/05/25 November 5, 2025 1 EN
Roy Külter ... (+2)
  • Roy Külter
  • Steven Boumans
CRI CHARGEURS SA
BVI BUREAU VERITAS SA
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
EVT EVOTEC SE
TNG TRANSGENE SA
ISS ISS A/S
ITRK INTERTEK GROUP PLC
BOSS HUGO BOSS AG
ACX ACERINOX SA
TRI TRIGANO SA
FAE FAES FARMA S.A.
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
ROYAL VOPAK NV
MONT MONTEA SCA
BPOST BPOST SA
CPINV CARE PROPERTY INVEST SA
TWEKA TKH GROUP N.V. CERT
DGM DIAGNOSTIC MEDICAL SYSTEMS
RUI RUBIS SCA
DIGI DIGI COMMUNICATIONS NV
GEST GESTAMP AUTOMOCION S.A.
ALFEN ALFEN NV
HFG HELLOFRESH SE
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
AG1 AUTO1 GROUP
SGSN SGS SA
SHA SCHAEFFLER AG
11/05/25 November 5, 2025 1 FR

ResearchPool Subscriptions

Get the most out of your insights

Get in touch